https://resiconference.com/digital-resi-three-day-conference/
https://resiconference.com/innovation-challenge-5/
Cybrexa at the 2020 BTIG Virtual Biotechnology Conference (August 10-11)
Cybrexa will host a Fireside Chat and investor meetings at the 2020 BTIG Virtual Biotechnology Conference on August 11. Register via https://www.btig.com/news/btig-virtual-biotechnology-conference/
Cybrexa Presents New Data for CBX-12 and CBX-13 at the AACR Virtual Annual Meeting II
Cybrexa Poster – CBX13 Cybrexa Poster – CBX12
This week we are presenting new preclinical data for our lead program, CBX-12 (alphalex-exatecan) and CBX-13 (alphalex-DM4) at the AACR Virtual Annual Meeting II.
Register for free and check out our e-posters at:
https://vcusa.sparx-ip.net/aacr2020ep/?view=1&searchfor=cybrexa&c=a&item=2020AB_6249
https://vcusa.sparx-ip.net/aacr2020ep/?view=1&searchfor=cybrexa&c=a&item=2020AB_6242
Cybrexa Therapeutics is Presenting, Speaking on a Panel at BIO Digital June 8-12, 2020
BIO Digital (June 8th-12th)
- https://www.bio.org/events/bio-digital
- Cybrexa company presentation will be available on demand starting on June 8
- Cybrexa CEO Per Hellsund and VP, Corporate Development Keely Zipp are also speaking on the panel ‘Getting to the Tumor: Beyond the First Generation of Tumor Targeting Technologies’ available on demand June 8-12
- Be sure to register and join us online: https://www.bio.org/events/bio-digital/sessions/620419
6TH Annual Immuno-oncology Innovation Forum (May 26-27th)
-
- https://www.sachsforum.com/
Cybrexa is Presenting, Speaking on a Panel at the Sachs 6th Annual Digital Immuno-Oncology Innovation Forum, May 26-27, 2020
- Cybrexa will present at the Sachs 6th Annual Digital Immuno-Oncology Innovation Forum that is being held May 26-27, 2020
- Per Hellsund, CEO will also be a member of the ‘Latest Trends in C&G Therapeutics II: Focusing on Cancer Vaccines, Neo Antigens & Other Modalities’ panel which will be broadcast live on Wednesday, May 27, 2020 at 11am ET.
- Access to this conference is free for investors via the link: https://www.sachsforum.com/6ioif-registration.html
Cybrexa Presents at 2020 J.P. Morgan Yale Innovation Dinner
Many thanks to Yale’s Office of Cooperative Research and Biohaven Pharmaceuticals for Co-Hosting
Cybrexa to present at the PARP and DDR Inhibitors Summit in Boston January 28-30
https://parp-ddr-inhibitors-summit.com/program/agenda/
AACR 2019 Poster – Tumor-selective CBX-11 (alphalex™-rucaparib) allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors
https://www.cybrexa.com/wp-content/uploads/2019/04/Cybrexa-Poster-2981-AACR-Mtg-Atlanta-Mar2019-002.pdf